Cytokinetics Stock News

Commodities were the only major index to gain ground last week. Read here for a detailed review...

Cytokinetics Inc (CYTK) shares closed this week 22.9% lower than it did at the end of last week. The stock is currently down 22.9% year-to-date, up 63.3% over the past 12 months, and up 170.4% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Shares traded as high as $46.95 and as low as $34.00 this week.Shares closed 26.6% below its 52-week high and 98.4% above its 52-week low.Trading volume this week was 16.1% higher than the 10-day average and 38.4% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.3. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price lags the S&P 500 Index this week, beats it on a 1-year basis, and beats it on a 5-year basis The company's share price lags the Dow Jones Industrial Average this week, beats it on a 1-year basis, and beats it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector this week, beats it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 657.9% The company's stock price performance over the past 12 months beats the peer average by -283.4% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Cytokinetics establishes partnership deal with Royalty Pharma for omecamtiv mecarbil and aficamten. Up to $450 million in total is expected for this particular deal. NDA Filing of omecamtiv mecarbil f

Royalty Pharma Extends Capital to Cytokinetics to Support the Commercial Launch of Omecamtiv Mecarbil and the Further Development of Aficamten

SOUTH SAN FRANCISCO, Calif., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to p

Cytokinetics Inc (CYTK) shares closed 0.9% higher than its previous 52 week high, giving the company a market cap of $3B. The stock is currently up 114.9% year-to-date, up 113.3% over the past 12 months, and up 260.2% over the past five years. This week, the Dow Jones Industrial Average rose 1.6%, and the S&P 500 rose 2.3%. Trading Activity Trading volume this week was 32.6% lower than the 20-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 1.3. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , beats it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -566.7% The company's stock price performance over the past 12 months beats the peer average by -514.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Cytokinetics (NASDAQ:CYTK) had its target price hoisted by HC Wainwright from $62.00 to $69.00 in a report published on Tuesday morning, Analyst Price Targets reports. The brokerage currently has a buy rating on the biopharmaceutical companys stock. Several other research firms have also recently weighed in on CYTK. Jefferies Financial Group started coverage on Cytokinetics [] The post HC Wainwright Raises Cytokinetics (NASDAQ:CYTK) Price Target to $69.00 appeared first on ETF Daily News .

Cytokinetics, Incorporated (NASDAQ:CYTK) Director Edward M. Md Kaye sold 15,000 shares of the stock in a transaction on Thursday, December 23rd. The stock was sold at an average price of $45.00, for a total value of $675,000.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. []

Equities researchers at Oppenheimer started coverage on shares of Cytokinetics (NASDAQ:CYTK) in a report released on Tuesday, The Fly reports. The brokerage set an outperform rating and a $55.00 price target on the biopharmaceutical companys stock. Oppenheimers price target indicates a potential upside of 24.94% from the companys current price. CYTK has been the subject [] The post Oppenheimer Initiates Coverage on Cytokinetics (NASDAQ:CYTK) appeared first on ETF Daily News .

Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) reached a new 52-week high on Wednesday after HC Wainwright raised their price target on the stock from $62.00 to $69.00. HC Wainwright currently has a buy rating on the stock. Cytokinetics traded as high as $43.70 and last traded at $43.70, with a volume of 10808 shares traded. The []

JI XING to Develop and CommercializeNovel Cardiac Myosin Activator in Patients with Heart Failure

JPMorgan Chase & Co. started coverage on shares of Cytokinetics (NASDAQ:CYTK) in a research note issued to investors on Friday morning, Analyst Price Targets reports. The brokerage issued an overweight rating and a $58.00 target price on the biopharmaceutical companys stock. Several other equities research analysts have also recently commented on CYTK. Mizuho boosted their []

The FDA bestows a Breakthrough Therapy status on Cytokinetics' (CYTK) aficamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy.

DUBLIN--(BUSINESS WIRE)--The "Global Spinal Muscular Atrophy Treatment Market (2021-2026) by Disease Type, Treatment, Route of Administration and Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com''s offering. The Global Spinal Muscular Atrophy Treatment Market is estimated to be USD 1.1 Bn in 2021 and is expected to reach USD 1.98 Bn by 2026, growing at a CAGR of 12.5%. The SMA treatment market is growing at a signifi